In this study, we analyzed the safety and efficacy of the re-administration of gilteritinib in a patient with FLT3-mutated relapsed/refractory (R/R) AML with central nervous system (CNS) relapse soon after bridging HSCT with gilteritinib. Here, FLT3 is linked to acute myeloid leukemia.